**STRIDES PHARMA INTL** announced that on October 13, 2026, the FDA approved its Abbreviated New Drug Application (ANDA #208359), which is expected to allow for the late-entry market launch of generic competition to address [implied substance], thereby placing downward pressure on brand pricing throughout the sector.